Core Insights - The rapid development of internet technology, diverse audience demands for entertainment content, supportive policies, and the entry of internet giants like Douyin and Kuaishou have led to a significant explosion in China's short drama industry, with a market size projected to reach 50.5 billion yuan in 2024, a year-on-year increase of 35% [1][5][6] - The global AI short drama market has entered a phase of explosive growth since the second half of 2024, with notable advancements in AI video generation models enhancing production efficiency and creativity [1][7][9] AI Short Drama Industry Overview - AI short dramas utilize artificial intelligence to generate visuals, plots, and other elements, significantly reducing production time to "hour-level" and costs to as low as 1% of traditional methods [3][4] - The industry has evolved through four stages: technology emergence (2018-2020), tool exploration (2021-2022), industry explosion (2023-2024), and ecosystem formation (2025 onwards) [3][4] AI Short Drama Industry Policies - The Chinese government has implemented various policies to promote the AI short drama industry, including the 2025 notice encouraging innovation in micro-short drama creation and integration with AI technology [5][6] Current Development of AI Short Drama Industry - The short drama format has gained popularity due to its suitability for fragmented viewing time, with several high-quality productions emerging, such as "Escape from the British Museum" and "My Return Journey Has Wind" [1][5] - The market size for short dramas in China is expected to reach 50.5 billion yuan in 2024, reflecting a 35% increase from the previous year [1][6] AI Short Drama Industry Competition Landscape - The competition in the AI short drama industry involves technology vendors (e.g., Baidu, Tencent), content producers (traditional and new teams), and platform operators (Douyin, Kuaishou, Bilibili) [9][10] AI Short Drama Industry Development Trends - Continuous technological innovation will drive the expansion of AI short dramas, with advancements in real-time animation and emotional algorithms enhancing artistic expression [13][14] - "Human-machine collaboration" will be crucial for improving the quality of AI short dramas, allowing creators to focus on core storytelling while AI handles complex visual elements [14][15] - Interactivity and personalization will distinguish AI short dramas from traditional media, enabling viewers to influence storylines and customize characters, thus enhancing engagement [15]

Core Viewpoint - The announcement highlights the commencement of filming for the drama "Small Town Prescription," produced by Lingmeng Film and co-produced by iQIYI, indicating a strategic collaboration in the entertainment industry [1] Group 1: Production Details - The drama "Small Town Prescription" began filming on October 18, 2025 [1] - The script is written by Nie Chengshuai, directed by Zhang Xiaobo, with Su Xiao as the executive producer and Xia Jie as the producer [1] Group 2: Cast Information - The lead role is played by the prominent young actor Xiao Zhan, supported by a strong cast including Ni Dahong, Jiang Yan, Shi Pengyuan, Kan Renzi, and Zhang Guoqiang [1]

Core Viewpoint - The article announces that Ningmeng Film and Television (09857.HK) has commenced filming for the healing drama "Small Town Prescription," co-produced with iQIYI, starting on October 18, 2025 [1] Group 1 - The drama "Small Town Prescription" is produced by Ningmeng Film and Television and co-produced by iQIYI [1] - The script is written by Nie Chengshuai, directed by Zhang Xiaobo, with Su Xiao as the executive producer and Xia Jie as the producer [1] - The lead role is played by popular young actor Xiao Zhan, alongside notable actors Ni Dahong, Jiang Yan, Shi Pengyuan, Guan Renzi, and Zhang Guoqiang [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Linmon Media Limited 承董事會命 檸萌影視傳媒有限公司 9857 自願公告 業務發展最新情況 本公告乃經檸萌影視傳媒有限公司（「本公司」或「檸萌影視」，連同其附屬公司及併表聯屬 實體統稱「本集團」）自願作出，旨在向本公司股東及潛在投資者更新本集團之最新業務發 展。 本公司董事會（「董事會」）欣然宣佈，由檸萌影視出品，愛奇藝聯合出品的小城生活「療」 愈劇《小城良方》，已於2025年10月18日開機拍攝。該劇由聶成帥編劇，張曉波導演，蘇 曉擔任總製片人，夏傑擔任製片人，實力青年演員肖戰領銜主演，倪大紅、姜妍、史彭 元、菅紉姿、張國強領銜主演。 董事長 蘇曉 中國，北京 2025年10月20日 於本公告日期，本公司執行董事為蘇曉先生、陳菲女士及徐曉鷗女士；本公司非執行董 事為王娟女士及張嶸先生；本公司獨立非執行董事為蔣昌建先生、唐松蓮女士及梁寧女 士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 檸萌影視傳媒有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09857 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股 ...

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

智通财经APP讯，柠萌影视(09857)发布公告，由国家安全部重点指导，中央广播电视总台、中国电视剧 制作中心、柠萌影视及旗下柠萌开新、腾讯视频出品的当代国安题材电视剧《交锋》，已于2025年9月 29日开机拍摄。该剧由王小枪编剧，姚晓峰总导演，张翼芸担任总制片人，王凯领衔主演，彭昱畅特别 主演，欧豪特邀主演。 ...

自願公告 業務發展最新情況 本公告乃經檸萌影視傳媒有限公司（「本公司」或「檸萌影視」，連同其附屬公司及並表聯署 實體統稱「本集團」）自願作出，旨在向本公司股東及潛在投資者更新本集團之最新業務發 展。 本公司董事會（「董事會」）欣然宣佈，由國家安全部重點指導，中央廣播電視總台、中國 電視劇製作中心、檸萌影視及旗下檸萌開新、騰訊視頻出品的當代國安題材電視劇《交 鋒》，已於2025年9月29日開機拍攝。該劇由王小槍編劇，姚曉峰總導演，張翼芸擔任總 製片人，王凱領銜主演，彭昱暢特別主演，歐豪特邀主演。 承董事會命 檸萌影視傳媒有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Linmon Media Limited 9857 董事長 於本公告日期，本公司執行董事為蘇曉先生、陳菲女士及徐曉鷗女士；本公司非執行董 事為王娟女士及張嶸先生；本公司獨立非執行董事為蔣昌建先生、唐松蓮女士及梁寧 女士。 蘇曉 中國，北京 2025年9月29日 ...

Drama Production and Content Strategy - By the end of June 2025, the Group has produced and distributed a total of 26 high-quality drama series, with 24 being original series where the Group acted as the lead/sole investor and executive producer[7]. - The Group's original drama series include popular titles such as "A Love for Separation," "Nothing but Thirty," and "Novoland: Eagle Flag," focusing on contemporary themes like family life and female empowerment[9]. - The Group is committed to diversified growth strategies, exploring new avenues such as content marketing, short drama series, overseas business, and IP derivative development to maximize the commercial value of proprietary IP rights[10]. - The original drama series "A Dream within a Dream" achieved significant viewership, with over 8 billion views on Douyin, ranking TOP1 among drama series during the same period[35]. - Several new projects are in preparation, scheduled to start shooting in the second half of 2025, including "A Journey to Glow" and "Showdown"[35]. - The Group aims to produce over 200 episodes of long drama series throughout 2025, focusing on premium original content[47]. - The Group is actively exploring the production and distribution of mini and short drama series in niche languages, with several projects currently in production[43]. - The Group's short commercial-break dramas achieved significant popularity, with multiple titles ranking TOP1 on various platforms[41]. Financial Performance - Revenue for the six months ended June 30, 2025, amounted to approximately RMB 401.3 million, representing an increase of 109% from approximately RMB 192.5 million for the same period in 2024[24]. - Gross profit for the same period was approximately RMB 101.0 million, an increase of 140% from approximately RMB 43.0 million in 2024[24]. - Net profit for the six months ended June 30, 2025, was approximately RMB 11.3 million, compared to a net loss of approximately RMB 52.9 million for the same period in 2024[24]. - Adjusted net profit for the same period was approximately RMB 14.4 million, a turnaround from an adjusted net loss of approximately RMB 49.4 million in 2024[24]. - The Group's total revenue increased by 109% from RMB192.5 million for the six months ended June 30, 2024, to RMB401.3 million for the six months ended June 30, 2025, primarily due to the launch of the 40-episode drama "A Dream within a Dream"[55]. - Gross profit rose by 135% from RMB43.0 million for the six months ended June 30, 2024, to RMB100.99 million for the six months ended June 30, 2025[58]. - The gross profit margin improved by 2.8 percentage points from 22.4% for the six months ended June 30, 2024, to 25.2% for the six months ended June 30, 2025[59]. - The Group's cost of sales increased by 101% from RMB149.5 million for the six months ended June 30, 2024, to RMB300.3 million for the six months ended June 30, 2025[57]. - Other income and gains decreased by 39.4% from RMB46.5 million for the six months ended June 30, 2024, to RMB28.2 million for the six months ended June 30, 2025[63]. - Administrative expenses decreased by 24.6% from RMB99.0 million for the six months ended June 30, 2024, to RMB74.7 million for the six months ended June 30, 2025[65]. - Finance costs increased by 56.7% to RMB2.3 million for the six months ended June 30, 2025, from RMB1.5 million for the six months ended June 30, 2024[66]. - The Group recorded a net profit of RMB11.3 million for the six months ended June 30, 2025, compared to a net loss of RMB52.9 million for the six months ended June 30, 2024[76]. - Income tax expense decreased to RMB1.5 million for the six months ended June 30, 2025, from RMB6.3 million for the six months ended June 30, 2024, due to the utilization of deductible losses from previous years[68]. - Revenue growth was driven by the broadcast of quality drama series and improved financial performance from new business lines such as short drama series[84]. Overseas Business and Distribution - The Group's overseas distribution revenue recorded notable growth year-on-year, with the first overseas localized long drama series recently broadcasting[27]. - The Group's overseas business revenue exceeded RMB 33 million in the first half of 2025, approximately 2.5 times higher than the same period in 2024[42]. - The original drama series "A Dream within a Dream" ranked TOP1 on the iQIYI International platform across eleven countries and regions in the first half of 2025[43]. Employee and Workforce Diversity - As of June 30, 2025, the Group had 185 employees, with approximately 76.8% being female, reflecting a commitment to workforce diversity[50][52]. Corporate Governance and Compliance - The company has adopted the Model Code for Securities Transactions by Directors and confirmed compliance by all Directors for the six months ended June 30, 2025[122]. - The company will continue to review its corporate governance practices to ensure compliance with the CG Code[117]. - The company has established an Audit Committee to oversee financial reporting, internal controls, and risk management, comprising one non-executive Director and two independent non-executive Directors[126]. - The Board believes that the current structure of the Chairman and CEO roles, held by Mr. Su, will not impair the balance of power and authority within the company[116]. - The overall strategic and key business policies of the company are made collectively after thorough discussion among all Board members and senior managers[116]. Shareholder Interests and Options - The interests of directors and chief executives in the company include Mr. Su, Ms. Chen, and Ms. Xu, each holding approximately 37.94% of the shares through controlled corporations[142]. - As of June 30, 2025, Mr. Su directly holds 71,136,000 shares in the company[144]. - Faye Free Flight Limited and A&O Investment Limited, both wholly owned by Ms. Chen and Ms. Xu respectively, each hold 33,014,520 shares in the company[144]. - The direct interest held by Mr. Su, Ms. Chen, and Ms. Xu in Shanghai Linmon is 56.93%[149]. - The Pre-IPO Share Option Scheme allows for a maximum of 14,680,471 shares to be issued, which is 4.06% of the total issued shares as of the interim report date[165]. - As of June 30, 2025, 11,906,964 options have been granted under the Pre-IPO Share Option Scheme, representing 3.29% of the total issued shares[165]. - The 2024 Share Option Scheme allows for a maximum of 36,045,882 shares to be issued, representing 9.97% of the total issued shares of 361,575,527 as of the interim report date[190]. - The maximum number of shares issuable to service provider participants is 18,022,941, which is 4.98% of the total issued shares[190]. - The option exercise price will be determined by the Board and must be at least the higher of a specified minimum[200].

Core Viewpoint - The announcement highlights the commencement of filming for the urban medical emotional drama "Asking the Heart 2," produced by Lingmeng Film and Television, Tencent Video, and iQIYI, indicating a strategic collaboration among major players in the media industry [1] Group 1: Production Details - "Asking the Heart 2" began filming on September 27, 2025 [1] - The series is written by Zhou Yifei and directed by Li Zhi, with Xu Xiaowu serving as the executive producer [1] - Notable cast members include Zhao Youting and Mao Xiaotong in leading roles, with Jin Shijia in a special role and Zhang Jianing as a guest lead [1]